RxDoctor Payments DataLook up a doctor →

Carter Capra, MD

Hematology & Oncology · Birmingham, ALNPI 1033559430

Payments from drug & device makers

$67,613in general payments, 2019–2025

Across 1,063 payments — averaging $63.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$48K
  • AstraZeneca$3K
  • Novartis$2K
  • Bristol Myers Squibb$968
  • Merck$929
  • Johnson & Johnson$902
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.92$47,989
AstraZeneca(2 entities)65$2,888
Novartis119$2,029
Bristol Myers Squibb55$968
Merck49$929
Johnson & Johnson(2 entities)66$902
Seagen Inc.38$604
AbbVie29$592
Pfizer32$521
Amgen28$515
Daiichi Sankyo Inc.24$506
Eisai Inc.28$473
Incyte Corporation25$460
Ipsen Biopharmaceuticals, Inc21$448
Takeda Pharmaceuticals U.S.A., Inc.21$447
Genentech USA, Inc.24$432
Sanofi19$398
Sobi, Inc16$375
Lilly USA, LLC21$334
Gilead(2 entities)17$283
Stemline Therapeutics Inc.12$278
Pharmacyclics LLC, An Abbvie Company15$253
Deciphera Pharmaceuticals Inc.10$240
Beigene USA, Inc.14$239
Myriad Genetic Laboratories, Inc.12$224
Regeneron Healthcare Solutions, Inc.12$196
GSK10$191
Exelixis Inc.10$190
Pharmaessentia USA Corporation9$177
Immunocore Limited3$168
Intera Oncology, Inc1$167
Bayer9$155
Pharmacosmos Therapeutics Inc.6$150
Karyopharm Therapeutics Inc.8$146
Beone Medicines USA, Inc.8$144
Tesaro, Inc.7$134
Astellas Pharma US Inc7$129
Puma Biotechnology, Inc.7$125
Springworks Therapeutics, Inc.4$98
Octapharma USA, Inc.1$97
Sumitomo Pharma America, Inc.5$97
Iovance Biotherapeutics, Inc.4$96
AVEO Pharmaceuticals, Inc.5$96
Blueprint Medicines Corporation4$92
Genmab U.S., Inc.5$87
Servier Pharmaceuticals LLC5$85
ADC Therapeutics America, Inc.4$79
Jazz Pharmaceuticals Inc.4$77
Array Biopharma Inc4$70
EMD Serono, Inc.4$69
Boehringer Ingelheim3$67
Taiho Oncology, Inc.4$65
Epizyme, Inc.4$63
CSL Behring3$58
EUSA Pharma (US) LLC3$49
Pharming Healthcare, Inc.2$49
Aurobindo Pharma USA, Inc.3$49
Recordati_rare_diseases_inc.2$45
Acrotech Biopharma Inc.2$42
Shield Therapeutics Inc2$40

How this compares

$67,613 in reported general payments places this provider in the 65th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Medicare billing

Part B allowed, 2024
$4,741,161
Medicare patients
306
Services billed
156,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Birmingham

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →